Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

MLA

Nakajima, Shinichiro, et al. “Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.” Schizophrenia Bulletin, vol. 42, no. 1, Jan. 2016, pp. 212–19. EBSCOhost, https://doi.org/10.1093/schbul/sbv106.

APA

Nakajima, S., Uchida, H., Bies, R. R., Caravaggio, F., Suzuki, T., Plitman, E., Mar, W., Gerretsen, P., Pollock, B. G., Mulsant, B. H., Mamo, D. C., & Graff-Guerrero, A. (2016). Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Schizophrenia Bulletin, 42(1), 212–219. https://doi.org/10.1093/schbul/sbv106

Chicago

Nakajima, Shinichiro, Hiroyuki Uchida, Robert R Bies, Fernando Caravaggio, Takefumi Suzuki, Eric Plitman, Wanna Mar, et al. 2016. “Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.” Schizophrenia Bulletin 42 (1): 212–19. doi:10.1093/schbul/sbv106.